On February 24, 2021, Sunesis Pharmaceuticals, Inc. (the “Company”) completed its business combination with Viracta Therapeutics, Inc. Pursuant to the Merger Agreement, on February 24, 2021, effective as of the Effective Time, Steve R. Carchedi, Steven B. Ketchum, Ph.D., Homer L. Pearce, Ph.D., David C. Stump, M.D., H. Ward Wolff, and James W. Young, Ph.D. resigned from the Board and any respective committees of the Board on which they served, which resignations were not the result of any disagreements with the Company relating to the Company’s operations, policies or practices. Also, pursuant to the Merger Agreement, on February 24, 2021, effective as of the Effective Time, the Company terminated the employment of Parvinder S. Hyare, the Company’s interim Chief Executive Officer, Tina Gullota, the Company’s Principal Financial Officer, and Judith A. Fox, Ph.D., the Company’s Chief Scientific Officer. Effective as of the Effective Time, the Board appointed Ivor Royston, M.D., as the Company’s Chief Executive Officer and President, Daniel Chevallard as the Company’s Chief Financial Officer and Secretary, and Lisa Rojkjaer, M.D., as the Company’s Chief Medical Officer. Effective as of the Effective Time, Gur Roshwalb, M.D., Sam Murphy, Ph.D., and Thomas E. Darcy were appointed to the audit committee of the Board, and Mr. Darcy was appointed as the chairman of the audit committee. Effective as of the Effective Time, Roger J. Pomerantz, M.D., Nicole Onetto, M.D. and Thomas E. Darcy were appointed to the compensation committee of the Board, and Dr. Onetto was appointed as the chairman of the compensation committee. Effective as of the Effective Time, Roger J. Pomerantz, M.D., Gur Roshwalb, M.D., and Michael Huang, M.S., M.B.A. were appointed to the nominating and corporate governance committee of the Board, and Dr. Pomerantz was appointed as the chairman of the nominating and corporate governance committee.